SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes ...

The FDA is proposing the removal of phenylephrine, a popular nasal decongestant, in oral form from over-the-counter use. Here ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Summit Therapeutics may have a powerful new cancer therapy on its hands. Merck is milking its cash cow oncology drug and ...

Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Its top-selling treatment, Keytruda, will lose patent protection in a few years. Then Merck will face biosimilar competition ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...

Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange ...

Ideaya Biosciences has decided to go ahead with its plans to grab a bispecific antibody-drug conjugate (ADC) from Biocytogen, exercising an option to pick up a preclinical asset from the Chinese ...